Titan Pharmaceuticals Inc. (NASDAQ:TTNP) traded today at a new 52-week low of $2.21. Approximately 58.9 million shares have changed hands today, as compared to an average 30-day volume of 666,000 shares.
Titan Pharmaceuticals Inc is a specialty pharmaceutical company. It is engaged in the development and commercialization of pharmaceutical products. The company product pipeline consists of Probuphine for Opioid addiction, Ropinirole for Parkinson’s disease, Triiodothyronine (T3) for hypothyroidism. It generates revenue principally from collaborative research and development arrangements, technology licenses, and government grants.
Titan Pharmaceuticals Inc. share prices have moved between a 52-week high of $14.06 and the current low of $2.21 and are currently at $2.21 per share.
Potential upside of 31.1% exists for Titan Pharmaceuticals Inc., based on a current level of $2.21 and analysts’ average consensus price target of $2.90.
Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts
To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected
About InvestorBrandNetwork (IBN)
InvestorBrandNetwork (IBN) consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign.
For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer